The Global Parenteral Nutrition Market size is expected to reach $10.9 billion by 2027, rising at a market growth of 8.1% CAGR during the forecast period. Parenteral nutrition (parenteral nutrition), or intravenous feeding, provides liquid nutrients such as proteins, vitamins, fats, electrolytes, minerals, and carbohydrates. It is a component of specialized nutritional therapy that renders nutritional support to patients who are not able to use their gastrointestinal tract properly. It is extremely helpful in eliminating malnutrition and maintaining hydration, energy, and strength levels. Due to this, it is broadly utilized among patients who are suffering from cancer, hydration, Crohn?s disease, ischemic bowel disease, short bowel syndrome, and abnormal bowel function. The development of the parenteral nutrition market is expected to be fueled by the surge in the occurrence of malnutrition among children, mainly in the emerging and under-developed nations around the globe. Additionally, the requirement for parenteral nutrition (parenteral nutrition) to appropriately balance amino acids, lipids, vitamins, minerals, and other nutrients would create bright growth prospects for the growth of the parenteral nutrition market. The adoption of parenteral nutrition is expected to fuel as it reduces the chances of underdevelopment and infection. Very-Low-Birth-Weight (VLBW) newborns are witnessing a huge demand for parenteral nutrition products due to the low possibility of Enteral Nutrition (EN). Additionally, a surge in the acceptance of parenteral nutrition for premature infants that results in better neurological growth enhanced intrauterine nutrient deposition, and lower chances of complications, hence enhancing their possibility of survival. COVID-19 Impact The outbreak of the COVID-19 pandemic has substantially boosted the adoption rate of parenteral nutrition to offer the required nutrition and fluids needed by the body for rapid and safe recovery. In addition, the increasing acceptance of the administration of nutrition by the parenteral medium as compared to enteral feeding among the patients suffering from the COVID-19 for fulfilling the required nutritional needs, rising nutrient absorption, and declining infection risk is expected to accelerate the demand & growth of the overall parenteral nutrition market in the upcoming years. Moreover, the rising adoption of these formulations among the clinicians for assisting the patients to fulfill their target nutrition consumption, enhance recovery, and cut down the hospital stays are some of the factors propelling the development of the global parenteral nutrition market. Market Growth Factors: The surge in the rate of malnutrition among the global population In addition, the governments of numerous countries are undertaking various initiatives with an aim to cut down the growing burden of malnutrition, hence increased the intravenous feeding demand. Various government organizations such as Action against Hunger, Food4Africa, Heifer International, and World Health Organization are willing to take new initiatives that aim to offer better treatment for malnourished individuals. Higher prevalence of different chronic diseases Various kinds of diseases like head & neck cancer, esophageal cancer, Crohn's, ulcerative colitis, gastric cancer, and laryngeal cancer can have an impact on oral food consumption among the patients. Due to their increasing occurrence, the global parenteral nutrition market is expected to be propelled in the upcoming years. Market Restraining Factor: Increasing inclination toward enteral nutrition The preference toward enteral nutrition is constantly increasing among patients across the globe. Medical specialists generally suggest the use of enteral feeding in comparison to parenteral feeding. This is due to the fact that it is less expensive, can be easily administered, and have fewer complications. Moreover, enteral feeding enables better and effective nutrient consumption and supports the natural healing process of the body through the stimulation of the intestinal blood flow. Nutrient Type Outlook Based on Nutrient Type, the market is segmented into Single Dose Amino Acid Solution, Parenteral Lipid Emulsion, Carbohydrates, Trace Elements, and Vitamins & Minerals. The parenteral lipid emulsion segment would exhibit the fastest growth rate during the forecasting period. Growing occurrences of hospital malnutrition is the main factor boosting the demand for parenteral lipid emulsions in giving non-protein calories and essential fatty acids in patients, decreasing inflammation, and enhancing metabolic & clinical outcomes. Additionally, the demand of the segment in hospitals would be boosted by the increasing demand from severely suffering patients and the high rates of chronic diseases such as inflammatory bowel disease, cancer, and diabetes. Regional Outlook Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Asia-Pacific would display the fastest growth rate during the forecasting period. The regional market is expected to be boosted by the economic growth in different nations like India, Japan, and China and the supportive government initiatives along with the favorable reimbursement policies and growth of the healthcare industry. Additionally, the surge in the occurrence of chronic diseases, the rising awareness regarding the advantages of the nutrient types, and the growing number of parenteral nutrition users in some of the emerging countries of this region would create new growth avenues for the players operating in the regional parenteral nutrition market over the forecast years. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Vifor Pharma Management Ltd., Baxter International, Inc., Allergan PLC (AbbVie), B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Grifols S.A., Pfizer, Inc., ICU Medical, Inc., Anhui Medipharm Co., Ltd. and Aculife Healthcare Private Limited. Strategies Deployed in Parenteral Nutrition Market Jul-2021: Baxter Healthcare (Baxter) signed an agreement with Micrel Medical, a medical device company specializing in infusion therapy. Under this agreement, the companies would distribute Micrel Mini Rythmic PN+ infusion pump for Parenteral Nutrition (PN). Sep-2020: Baxter International received an approval from the U.S. Food and Drug Administration (FDA) for its new formulations of Clinimix Injections and Clinimix E Injections. This new Clinimix formulations include up to 80 g/L of amino acids, the highest protein in any multi-chamber bag present in the U.S., which makes it easier to outreach patient protein targets and also providing less fluid and dextrose than offered by prevailing formulations. Aug-2020: ICU Medical came into an agreement with Grifols, a Spanish multinational pharmaceutical and chemical manufacturer. This agreement aimed to issue a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP to customers in the United States. In addition, the agreement would expand ICU Medical?s non-PVC/non-DEHP portfolio to include 50 mL to 1000 mL container sizes. Aug-2019: Baxter International introduced Olimel N12 in Europe, which adds to the company?s olive oil-based parenteral nutrition (PN) triple-chamber bag portfolio. Olimel N12 integrates a high protein formulation with low glucose content, leading in the lowest energy to protein ratio accessible in a standardized, triple-chamber bag. Jul-2019: Baxter International unveiled Finomel in Europe, a ready-to-use triple-chamber bag for parenteral nutrition (PN). This launch expanded the company?s product line of leading premixed PN formulations and give healthcare providers with supplement options to fulfil adult patients? various nutritional requirements. Scope of the Study Market Segments covered in the Report: By Nutrient Type ? Single Dose Amino Acid Solution ? Parenteral Lipid Emulsion ? Carbohydrates ? Trace Elements, ? Vitamins & Minerals By Geography ? North America o US o Canada o Mexico o Rest of North America ? Europe o Germany o UK o France o Russia o Spain o Italy o Rest of Europe ? Asia Pacific o China o Japan o India o South Korea o Singapore o Malaysia o Rest of Asia Pacific ? LAMEA o Brazil o Argentina o UAE o Saudi Arabia o South Africa o Nigeria o Rest of LAMEA Companies Profiled ? Vifor Pharma Management Ltd. ? Baxter International, Inc. ? Allergan PLC (AbbVie) ? B. Braun Melsungen AG ? Fresenius SE & Co. KGaA ? Grifols S.A. ? Pfizer, Inc. ? ICU Medical, Inc. ? Anhui Medipharm Co., Ltd. ? Aculife Healthcare Private Limited Unique Offerings from KBV Research ? Exhaustive coverage ? Highest number of market tables and figures ? Subscription based model available ? Guaranteed best price ? Assured post sales research support with 10% customization free